Fate Therapeutics (FATE) Return on Equity (2016 - 2025)
Historic Return on Equity for Fate Therapeutics (FATE) over the last 13 years, with Q3 2025 value amounting to 0.65%.
- Fate Therapeutics' Return on Equity fell 1800.0% to 0.65% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.65%, marking a year-over-year decrease of 1800.0%. This contributed to the annual value of 0.56% for FY2024, which is 1600.0% down from last year.
- According to the latest figures from Q3 2025, Fate Therapeutics' Return on Equity is 0.65%, which was down 1800.0% from 0.65% recorded in Q2 2025.
- In the past 5 years, Fate Therapeutics' Return on Equity registered a high of 0.2% during Q2 2021, and its lowest value of 0.65% during Q3 2025.
- For the 5-year period, Fate Therapeutics' Return on Equity averaged around 0.46%, with its median value being 0.47% (2024).
- In the last 5 years, Fate Therapeutics' Return on Equity skyrocketed by 2500bps in 2021 and then plummeted by -3200bps in 2022.
- Fate Therapeutics' Return on Equity (Quarter) stood at 0.31% in 2021, then crashed by -97bps to 0.6% in 2022, then grew by 26bps to 0.45% in 2023, then decreased by -26bps to 0.57% in 2024, then decreased by -15bps to 0.65% in 2025.
- Its Return on Equity stands at 0.65% for Q3 2025, versus 0.65% for Q2 2025 and 0.61% for Q1 2025.